4,814 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Purchased by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC acquired a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,814 shares of the company’s stock, valued at approximately $388,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of PRCT. Principal Financial Group Inc. raised its stake in PROCEPT BioRobotics by 290.2% during the third quarter. Principal Financial Group Inc. now owns 68,617 shares of the company’s stock worth $5,498,000 after acquiring an additional 51,030 shares during the period. Los Angeles Capital Management LLC acquired a new stake in PROCEPT BioRobotics during the third quarter worth about $367,000. Oppenheimer & Co. Inc. acquired a new stake in PROCEPT BioRobotics during the third quarter worth about $842,000. KBC Group NV raised its stake in PROCEPT BioRobotics by 32.6% during the third quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after acquiring an additional 376 shares during the period. Finally, Swiss National Bank raised its stake in PROCEPT BioRobotics by 5.8% during the third quarter. Swiss National Bank now owns 95,400 shares of the company’s stock worth $7,643,000 after acquiring an additional 5,200 shares during the period. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Up 2.4 %

PROCEPT BioRobotics stock opened at $59.03 on Tuesday. The firm has a 50 day simple moving average of $70.07 and a 200-day simple moving average of $79.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The stock has a market capitalization of $3.24 billion, a PE ratio of -30.27 and a beta of 1.05. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, equities research analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Morgan Stanley dropped their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Truist Financial restated a “buy” rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).